Andrew Atz, MD
Interim Chair, Department of Pediatrics
Our sickle cell center offers many different clinical research trials to help improve the lives and find new treatments for those individuals living with sickle cell disease.
Emily Warner: Sickle Cell Research Program Manager
Brandi Day: Research Coordinator
Ashley Green: Research Coordinator
Karen Hawkins: Research Nurse
Joannie Hayes: Research Coordinator
Carly Lauer: Research Assistant
Katherine Williams-Turner: Sickle Cell State Coordinator
For more information or to see if you are eligible for a clinical trial today contact Emily Warner at 843-876-8614 or email@example.com.
Reset Trial: Phase III study for children and adults to evaluate the use of a new IV medication (Rivapansel) to decrease pain and hospitalization in patients with sickle cell disease
HESTIA 1: Phase I/II study to evaluate the use of Ticagrelor for the prevention of pain and complications in children with sickle cell anemia
FIRST: Phase III study to evaluate the use of a new iron chelator (Ferriprox) for patients with sickle cell disease and iron overload
HGB206: Phase I gene therapy and autologous transplant study
STRIDE: A bone marrow transplant study to evaluate outcomes in patients with sickle cell disease undergoing bone marrow transplant compared to standard of care
Calypso: A Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an improved Deferasirox Formulation (granules) in Pediatric Patients with Iron Overload.
GBT440-025: Phase II, Open-label, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease and Severe Anemia.
SGHY-001-A: Phase I, Open-label Safety Study of SANGUINATE Infusion in Patients with Acute Severe Anemia who are unable to receive Red Blood Cell Transfusion.
STAR- A: Multi-Center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: A sickle Transplant Alliance for Research (STAR) Project.
Point of care: We are working with Biomedomics to evaluate a new point of care test, Sickle SCAN™ to improve the diagnosis of patients with sickle cell disease at the bedside
The Lifespan Comprehensive Sickle Cell Center at MUSC Children's Health is working closely with our local foundations and national organizations to raise awareness and advocacy for sickle cell disease as well as to improve funding for this underserved condition.
(SC)2: Sickle Cell-South Carolina
(SC)2 is a program funded through the Duke Endowment Foundation to create a state network for sickle cell disease to improve the care for individuals living with sickle cell disease throughout the state through increased access to care, communication between providers, and partnerships.
(SC)2 Principal Investigator: Julie Kanter
(SC)2 Program Coordinator: Katherine Williams
(SC)2 Human Services Coordinator: Gary Link
The U.S. News & World Report rankings place the MUSC Children’s Hospital heart program among the top 20 in the country. Six MUSC Children’s Hospital divisions are honored in the rankings: